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Microparticles (MP) are small membranous particles (100-1000 nm) released under 2 
normal steady-state conditions and are thought to provide a communication network 3 
between host cells. Previous studies demonstrated that Mycobacterium tuberculosis 4 
(M.tb) infection of macrophages increased the release of MPs, and these MPs induced 5 
a proinflammatory response from uninfected macrophages in vitro and in vivo 6 
following their transfer into uninfected mice. To determine how M.tb infection 7 
modulates the protein composition of the MPs, and if this contributes to their 8 
proinflammatory properties, we compared the proteomes of MPs derived from M.tb-9 
infected (TBinf-MP) and uninfected human THP-1 monocytic cells. MP proteins were 10 
analysed by GeLC-MS/MS with spectral counting revealing 68 proteins with 11 
statistically significant differential abundances. The 42 proteins increased in 12 
abundance in TBinf-MPs included proteins associated with immune function (7), 13 
lysosomal/endosomal maturation (4), vesicular formation (12), nucleosome proteins 14 
(4) and antigen processing (9). Prominent among these were the type I interferon 15 
inducible proteins, ISG15, IFIT1, IFIT2, and IFIT3. Exposure of uninfected THP-1 16 
cells to TBinf-MPs induced increased gene expression of isg15, ifit1, ifit2, and ifit3 17 
and the release of proinflammatory cytokines. These proteins may regulate the 18 





1. Introduction 1 
Extracellular vesicles are small (0.05-1 µm) particles shed from the membrane of 2 
cells under normal steady-state conditions and in response to stimuli such as cellular 3 
stress [1]. In contrast to their original description as “platelet dust” [2], an increasing 4 
number of important cellular functions have been attributed to these vesicles, 5 
including intercellular communication, trafficking of molecular cargo (e.g. protein, 6 
nucleic acid), apoptosis, homeostasis and cellular waste disposal [1, 3-5].  7 
 8 
Extracellular vesicles are broadly classified according to their size and biogenesis. 9 
Exosomes are small vesicles, ~50-100 nm diameter, formed within the cell and 10 
released into the extracellular milieu via exocytosis [1]. Microparticles (MPs) (100-11 
1000 nm) are released via budding from the cell membrane under a regulated 12 
mechanism influenced by multiple stimuli, including Ca2+, ATP and cell specific 13 
factors (e.g. complement proteins) [6]. MPs contain proteins from the cell membrane, 14 
and increasing evidence demonstrates that MPs also contain actively packaged 15 
molecules, although the mechanism for this process is not well understood [3, 4]. 16 
Increased production of extracellular vesicles has been associated with a number of 17 
pathological states, including cancer and infectious diseases, such as tuberculosis 18 
(TB) [5, 7]. Deciphering the biological roles these vesicles play may lead to an 19 
improved understanding of different pathologies, as well as the discovery of potential 20 
pharmacological targets or biomarkers for diagnosis and monitoring of disease 21 
progression. 22 
 23 
TB remains a major threat to human health worldwide with an estimated 8.6 million 24 
new cases and 1.3 million deaths in 2012 alone [8]. A major challenge to TB 25 
 4 
healthcare is that current diagnostic tests rely heavily on the presence of 1 
Mycobacterium tuberculosis (M.tb) bacteria within patient sputum. The development 2 
of novel diagnostic tests for TB infection, which are not reliant on the isolation and 3 
culturing of bacteria, are urgently required. Extracellular vesicles shed into the blood 4 
could form the basis of a clinical diagnostic test due to the easy, non-invasive nature 5 
of a blood test. We have previously shown [7] using both in vitro and in vivo studies 6 
that macrophages infected with M. tb increase the release of MPs, and that these 7 
vesicles are proinflammatory both in vitro and in vivo.  8 
 9 
To determine what proteins may mediate or contribute to the proinflammatory nature 10 
of the MPs derived from M. tb-infected macrophages, we profiled and compared the 11 
proteomes of MPs derived from M. tb infected and uninfected human monocytic 12 
THP-1 cells. Proteins with increased abundance included the Type I interferon 13 
inducible proteins ISG15, IFIT1, IFIT2, and IFIT3. These data suggest a possible role 14 
for ISG15 and IFITs in the host response to M. tb infection, potentially influenced by 15 
the type I interferon signalling pathway. Additionally, the findings of this study 16 
provide candidate biomarkers of M. tb infection for further investigation. 17 
 5 
2. Materials and Methods 1 
2.1. Cell and Bacterial culture 2 
Human myelo-monocytic THP-1 cells were cultured and differentiated by the 3 
addition of 100 nM PMA (Sigma-Aldrich) for 48 h. M. tuberculosis H37Rv was 4 
cultured in supplemented Middlebrook 7H9 to mid-logarithmic phase [7]. Bacterial 5 
counts were determined by culturing samples for 3 weeks on Middlebrook 7H11-6 
supplemented agar [7]. 7 
 8 
2.2. M. tuberculosis H37Rv infection of THP-1 cells 9 
Differentiated THP-1 cells were cultured at 2 × 107 cells per flask for sufficient yields 10 
of MPs, while cultures for RT-PCR were 5 x 105 cells. Cells were infected with M. tb 11 
H37Rv for 4 h at a multiplicity of infection (MOI) of 1 or left uninfected, washed 12 
twice to remove extracellular bacteria, cultured for 4 and 24 h for RT-PCR and 13 
Western blotting experiments, and 72 h for MP isolation.  14 
 15 
2.3. MP isolation 16 
Isolation, quantitation and size distribution of MPs were performed according to the 17 
established protocol of Walters et al [7] (Methods S1). Proteins were extracted from 18 
MPs by resuspension and lysis in RIPA buffer with protease inhibitors for proteomic 19 
or western blot analysis.  For determination of functional effects of MPs on naïve 20 
THP-1 cells, MPs were resuspended in triple filtered PBS, and the MP concentration 21 
determined as previously described [7]. 22 
 23 
2.4. GeLC-MS/MS of M.tb infected and uninfected THP-1 derived MPs 24 
 6 
Protein concentrations of MP samples were estimated by BCA protein assay (Pierce, 1 
Rockford, IL, USA) according to the manufacturer’s instructions. A total of 20 µg of 2 
protein from M.tb-infected THP-1 cell-derived MPs (TBinf-MP) and uninfected THP-3 
1 cell derived MPs (UI-MP) were separated by SDS-PAGE (Methods S1). Each gel 4 
lane was cut into 12 individual gel slices of equal size, were reduced, alkylated and 5 
trypsin digested overnight at 37oC. Peptide samples were concentrated and desalted 6 
using prefabricated microcolumns containing Poros R2 resin (Perseptive Biosystems, 7 
Framingham MA) [9]. Peptides were subjected to reversed phase LC−MS/MS using 8 
either an automated Agilent 1100 nanoflow LC system (Agilent Technologies, Santa 9 
Clara CA) coupled to a QSTAR Elite mass spectrometer (Applied Biosystems) or an 10 
Ultimate 3000 nano-HPLC and autosampler system (Dionex, Amsterdam, 11 
Netherlands) coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Fischer 12 
Scientific). 13 
 14 
Analysis using the 1100/ QSTAR Elite MS instrumentation setup was conducted on a 15 
total of six biological replicates. Peptides were loaded onto a trapping column 16 
(Agilent Zorbax 300SB-C18, 0.3 mm x 5 mm, 5 µm, 300 Å), washed with buffer A 17 
(0.1% v/v formic acid (FA)) and subsequently loaded onto an analytical column 18 
(Agilent Zorbax 300SB-C18, 0.1 mm x 150 mm, 3.5 µm, 300 Å pore size). Peptides 19 
were eluted over 120 min using a gradient of 5-90% buffer B (0.1% v/v FA, 100% 20 
acetonitrile (ACN)) at a nanoflow rate of 300 nL/min. The eluent was subjected to 21 
positive ion nanoflow ESI MS/MS in an information dependent acquisition mode 22 
(IDA). MS survey scans were performed over the m/z range of 400-1800 (three 23 
scans), with the 3 most intense ions sequentially subjected to MS/MS scans. Further 24 
 7 
analysis to achieve greater proteomic coverage depth using an Ultimate 3000 nano-1 
HPLC /LTQ-Orbitrap Velos MS setup was performed as previously described [10].  2 
 3 
Peak lists were extracted from QSTAR Elite data using Analyst (version 2.0, Applied 4 
Biosystems) or from Orbitrap velos data by Mascot Daemon/extract_msn (Matrix 5 
Science, Thermo; London, UK), using the default parameters. All MS/MS data were 6 
submitted to Mascot (Matrix Science, London, UK; version 2.4.0) and X! Tandem 7 
(The GPM, thegpm.org; version CYCLONE (2010.12.01.1)) and searched against the 8 
SwissProt_2013_09 database (selected for Homo sapiens, 20272 entries), with trypsin 9 
as the proteolytic enzyme and a single possible missed cleavage. Fragment ion mass 10 
tolerances of 0.20 Da or 0.40 Da, and parent ion tolerances of 0.20 Da or 4 ppm were 11 
selected for QSTAR and Orbitrap data respectively. Oxidation of methionine, 12 
carbamidomethyl of cysteine and propionamide of cysteine were specified in Mascot 13 
as variable modifications. Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-14 
terminus, gln->pyro-Glu of the n-terminus, oxidation of methionine and 15 
carbamidomethyl of cysteine were specified in X! Tandem as variable modifications.  16 
 17 
Scaffold (version Scaffold_4.0.5, Proteome Software Inc., Portland, OR) was used to 18 
validate MS/MS based peptide and protein identifications. Peptide identifications 19 
were accepted if they exceeded specific database search engine thresholds. Mascot 20 
identifications required at least ion scores must be greater than both the associated 21 
identity scores and 30, 40 and 50 for, doubly, triply and quadruply charged peptides. 22 
X! Tandem identifications required at least -Log(Expect Scores) scores of greater than 23 
4.0. Protein identifications were accepted if they contained at least 2 identified 24 
peptides. Proteins that contained similar peptides and could not be differentiated 25 
 8 
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 1 
Proteins sharing significant peptide evidence were grouped into clusters. Proteins 2 
were annotated with GO terms from gene_association.goa_human (downloaded 3 
08/07/2013) [11]. Spectral counting was performed to determine differentially 4 
abundant proteins with the inverted β-binomial test applied to QSTAR-MS data to 5 
determine statistical significance for paired data [12]. Only pairs containing count 6 
data in both paired members could be included in the test and hence paired data 7 
containing a zero count were excluded from the test. Data were filtered for proteins 8 
with a fold change > 1.5 or < -1.5 and a p-value < 0.05. Where a protein was uniquely 9 
detected in either the infected or uninfected THP-1 derived MP then it was required to 10 
have been detected in at least 2 replicates to be considered for further analysis. The 11 
additional biological replicate analysed by LTQ Orbitrap-MS was aligned to further 12 
corroborate statistically significant results from the QSTAR-MS analysis. 13 
Bioinformatic analysis was aided with online resources including KEGG pathway 14 
analysis (www.genome.jp/kegg/pathway) [13], STRING (version 9.1, www.string-15 
db.org) [14], Vesiclepedia (version 2.1, www.microvesicles.org) [15] and Exocarta 16 
(version 4.1, www.exocarta.org) [16]. All mgf and raw data files associated with this 17 
manuscript can be accessed at http://goo.gl/yZrrKd. 18 
 19 
2.5. Treatment of uninfected THP-1 cells with UI-MP or TBinf-MP 20 
Differentiated THP-1 cells were stimulated with UI-MP or TBinf-MP at a ratio of 5 21 
MP’s per cell and cultured for 4, 24 and 48 h. Culture supernatants were harvested 22 
and cytokines measured by Cytometric bead array (BD Biosciences) according to the 23 
manufacturer’s instructions using an LSRFortessa flow analyzer (BD Biosciences) 24 
 9 
[7]. Cells were harvested in 1 mL Trisure reagent (Bioline, Australia) for RNA 1 
purification and RT-PCR.  2 
 3 
2.6. Quantitative reverse transcriptase real-time PCR 4 
Gene expression of isg15, ifit1, ifit2, ifit3 and ip10 was determined by RT-PCR 5 
(Methods S1).  6 
 7 
2.7. Western blot analysis 8 
The presence of ISG15 protein in uninfected and M. tb infected THP-1 cells was 9 
assessed by Western blot (Methods S1).  10 
 11 
3. Results 12 
3.1 Macrophage microparticle proteome in response to M. tb infection 13 
THP-1 cells were infected with M. tb H37Rv for 72 h. Microparticles were purified 14 
from the culture supernatants, and their proteomes analysed by a GeLC-MS/MS 15 
proteomic approach. UI-MP and TBinf-MP isolations were demonstrated to have 16 
similar size distributions (flow cytometry, Fig. S1; SEM [7]) and therefore proteomic 17 
analysis was conducted normalising samples by protein concentration. Briefly, 18 
microparticle proteins were separated by 1D-SDS-PAGE, gel lanes sliced into bands 19 
of equal size, proteins digested with trypsin, and analysed by RPLC-MS/MS using 20 
two mass spectrometry platforms. Six paired biological replicates were analysed by 21 
the 1100/ QSTAR Elite MS platform with the resulting data compiled and validated in 22 
Scaffold (Tables S3 and S4). We applied the inverted β-binomial test described by 23 
Pham and colleagues [12] to determine significant differences in the paired spectral 24 
count data. A total of 521 proteins (465 protein groups) were identified, with the 25 
 10 
majority (476 proteins) present in both MP samples with 25 unique to the TBinf-MP 1 
sample and 20 unique to the UI-MP sample (Fig. S2A). 24 proteins were significantly 2 
increased in abundance, 18 proteins uniquely identified in the TBinf-MP, while 14 3 
proteins were decreased in abundance in the TBinf-MP and 12 proteins uniquely 4 
identified in the UI-MP (Fig. S2C). Bioinformatic analysis revealed increased 5 
representations of proteins within the TBinf-MP including the lysosome proteins 6 
CD63 (LAMP3), LAMP2, L-amino-acid oxidase IL4I1 and sialin. Increased immune 7 
function proteins included HLA-A, fibronectin FN1, MHC antigen H13A and type I 8 
interferon (IFN)-inducible proteins, ISG15, IFIT1, IFIT2 and IFIT3. A total of ten 9 
proteins associated with vesicular formation or trafficking were increased in 10 
abundance in the TBinf-MP, including Rab-5C, Rab-7A and Rab-14, which are 11 
known to be critical for immunity to M. tb [17, 18] (Fig. 1, Table 1). An additional ten 12 
proteins associated with protein maturation and antigen presentation, including six 13 
members of a large chaperone multiprotein complex; PDIA6, PDIA4, HSPA5, 14 
HSP90B1, PPIB and Erp29 and antigen presentation-related proteins, PDIA3 and 15 
CANX, were also increased in abundance. Histone proteins, HIST1H2BD, 16 
HIST1H4A, H2AFV and H2AFY, were all identified at increased abundance in 17 
TBinf-MP and may correlate to an increase in nucleic acid content in the MPs. 18 
 19 
Proteins observed at decreased abundances in TBinf-MP compared to UI-MP largely 20 
clustered into protein groups associated with the cytoskeleton (7), membrane proteins 21 
(5) and vesicle formation (3) (Fig. S3, Table S7). Decreased abundances observed 22 
may be a result of increased MP release and absent de novo synthesis of these 23 
proteins. Membrane proteins, including CD109, SLC4A7, APOE and MFGE8, 24 
displayed decreased abundances in the TBinf-MP of the greatest magnitude.  25 
 11 
 1 
To complement our approach we performed one additional paired analysis on an 2 
Ultimate 3000 nano-HPLC /LTQ-Orbitrap velos MS platform to improve the depth of 3 
proteome coverage. We identified a total of 1198 proteins (1018 groups) with a 4 
minimum of two unique peptides detected (Table S5 and S6). Proteins identified 5 
unique to the TBinf-MP totaled 175, with 334 unique to the UI-MP and 689 proteins 6 
identified in both. To focus attention on differentially abundant proteins, likely to be 7 
present in biologically relevant abundances, we further filtered data for proteins with 8 
a minimum of 6 spectra, and considered those differentially abundant with spectral 9 
count fold changes of > 1.5 or < -1.5 (Fig. S2B). A total of 710 proteins were 10 
identified common to both TBinf-MP and UI-MP, with 75 proteins increased in 11 
abundance and 157 with decreased abundance in TBinf-MP, while 18 were unique to 12 
TBinf-MP and 58 unique to UI-MP (Fig. S2D). While the number of protein 13 
identifications from the Orbitrap-velos analysis was increased compared to that of the 14 
QSTAR analysis, the data sets were largely complementary as the percentages of 15 
proteins assigned to GO terms (biological process, cellular component, molecular 16 
function) were consistent (Fig. S4). Similarly, proteins displaying significant 17 
differential abundance in the QSTAR analysis showed similar changes in abundance 18 
in the Orbitrap (Table 1, S2). The Orbitrap analysis did detect IFIT1 and ISG15 in the 19 
UI-MP, although these were still more abundant in the TBinf-MP. Two additional 20 
type I IFN inducible proteins, IFITM3 and PLSCR1, were detected at increased 21 
abundance in the TBinf-MP.  22 
 23 
3.2 M. tb infection of macrophages induces increased type I IFN inducible gene 24 
expression and protein abundance 25 
 12 
We next determined whether the increased abundances of type I IFN inducible 1 
proteins observed in the TBinf-MP correlated with increased abundance in the 2 
infected THP-1 cells, from which they were derived. THP-1 cells infected with M. tb 3 
were harvested at 4 and 24 h. Increased transcripts for multiple type I IFN inducible 4 
proteins, including ifits, isg15 and ip10 (Fig 2A), were detected. In addition, M. tb 5 
infection induced a 2-fold increase in free-ISG15 protein abundance and a 4-fold 6 
increase in ISGylated protein abundance at 24 h (Fig. 2B, 2C)  7 
 8 
3.3 Microparticles from M. tb infected macrophages induce expression of type I 9 
IFN inducible genes and cytokines in uninfected macrophages  10 
We have previously demonstrated that MPs are involved in intercellular 11 
communication between macrophages [7]. Therefore we investigated whether TBinf-12 
MPs induced gene expression of the IFN inducible genes ifit1, ifit2, ifit3, ifitm1/3, 13 
isg15 and ip10 upon uptake by recipient cells. THP-1 cells were stimulated with 14 
purified MPs at a 5:1 MP:cell ratio for 24 hr. Statistically significant increases in 15 
transcript for ifit1, ifit2, ifit3, ifitm1/3 and isg15, but not ip-10, were observed (Fig 16 
3A). We also measured the release of IP-10 protein and two common pro-17 
inflammatory cytokines, IL-8 and MIP-1, in the supernatants of the MP stimulated 18 
cells. The addition of TBinf-MP, but not UI-MPs, significantly increased the release 19 
of all three cytokines within 24 h of stimulation (Fig 3B). Interestingly, this included 20 
the release of considerable amounts of IP10, despite the fact that there was no 21 
increase in ip10 mRNA transcript at this time. This suggests that these cells may have 22 
either increased translation of ip10 mRNA, increased IP10 protein stability or an 23 
intracellular store of IP10, which is readily secreted without the need for further gene 24 
expression of IP10. 25 
 13 
4. Discussion 1 
Extracellular microvesicles, including exosomes and MPs, represent a novel source of 2 
biomarkers for multiple disorders, including cancers and infectious diseases. Our 3 
analysis of the MP proteome following M.tb infection provides evidence for an 4 
important functional role in innate immunity and has highlighted promising 5 
biomarker candidates for further studies.  6 
 7 
Analysis of the MP proteome following M.tb infection identified 68 differentially 8 
abundant proteins, including several type I IFN inducible proteins, the IFITs and 9 
ISG15. Very little is known about the role of ISG15 in M.tb infection, however 10 
patients with mutations in isg15, leading to a loss of ISG15 protein, are highly 11 
susceptible to mycobacterial disease [22]. ISG15 is highly expressed in lymphocytes, 12 
monocytes and the lung and is induced by both IFN-α and IFN-β [23]. We also 13 
observed the induction of isg15 with IFN-γ (data not shown). ISG15 is present both 14 
within cells and extracellularly, and can exist as a free form or conjugated to other 15 
proteins via an ubiquitination-like three-enzyme pathway, termed ISGylation [23]. 16 
Our data demonstrates that M.tb infection induced an increased abundance of both 17 
free and conjugated ISG15, suggesting a potential role for both in TB immunity. Free 18 
ISG15 can stimulate the proliferation of NK and T cells, the secretion of IFN-γ, and 19 
cell-mediated killing [24]. Furthermore, investigations in human patients with an 20 
isg15 mutation have attributed an important role for free intracellular ISG15 in the 21 
prevention of IFN-α/β-dependant autoinflammation [25]. As the mature ISG15 22 
protein lacks a defined secretion signal, MP release may provide an alternate means 23 
of secretion for ISG15. ISGylation of proteins has been linked with the regulation of 24 
signal transduction pathways, including JNK and NF-κB [26]. While it appears 25 
 14 
ISGylation is not as common as other types of PTMs (e.g. phosphorylation), there are 1 
still over 300 proteins that are candidates for ISGylation, and these are involved in 2 
diverse functions from central metabolism, RNA processing and protein translation, 3 
to chromatin remodelling and cytoskeletal organisation, suggesting that the impact of 4 
ISGylation may be widespread [27-29]. While an essential role for ISG15 and 5 
ISGylation in anti-viral immunity has been demonstrated [30][31], the role of ISG15 6 
in immunity to bacterial infection has largely been unexplored. A recent study, 7 
however, demonstrated that modulation of ISGylation is critical for resistance against 8 
Salmonella typhimurium and virulent M.tb, but not against the less virulent vaccine 9 
strain, Mycobacterium bovis BCG [32]. Interestingly, a number of ISGylation 10 
candidates are also type I IFN inducible proteins, including the IFIT proteins, which 11 
we observed at increased abundance in the TBinf-MP [27]. 12 
 13 
Similar to ISG15, the IFIT protein family in humans (IFIT1, IFIT2, IFIT3 and IFIT5) 14 
have been largely studied in the context of antiviral immunity [33]. Their gene 15 
expression is rapidly induced by type I IFNs or by stimulation with PAMPs, and the 16 
type of IFIT and the kinetics of expression are dependant on the cell and tissue type 17 
[34]. IFITs mediate antiviral immunity by inhibiting viral mRNA translation through 18 
multiple steps or by sequestering viral RNA, resulting in the inhibition of viral 19 
replication [33]. While increased ifit gene expression has been observed in M.tb 20 
infection, no functional role in anti-bacterial immunity or role in MP biology has been 21 
determined [19-21].  22 
 23 
Alignment with a compendium of previously identified microvesicle components 24 
(www.vesiclepedia.com), including viral infection studies, revealed that this is the 25 
 15 
first study to identify ISG15 and IFITs present in microvesicles [15]. This suggests 1 
that their presence in MPs is possibly due to a specific characteristic of, or stimulus 2 
to, the cell of origin (M.tb infection) leading to increased expression within the cell 3 
and consequently in the MP. Whether the presence of ISG15, IFIT1, IFIT2 and IFIT3 4 
proteins in the TBinf-MPs are due to the increased synthesis in the cell of origin 5 
alone, or also involves active packaging into MPs will require further investigation. 6 
As type I IFN inducible proteins may have an important role in the innate immune 7 
response to M.tb, we hypothesised that TBinf-MPs may mediate a signal inducing 8 
their biosynthesis in distal cells. Exposing uninfected THP-1 cells to TBinf-MP, 9 
indeed, resulted in the induction of isg15, ifit1, ifit2, ifit3 and ifitm1/3 gene 10 
expression, in addition to the increased release of pro-inflammatory cytokines (IL-8, 11 
MIP-1α and IP-10).  12 
 13 
This study contributes further evidence for the important role of IFNs in the innate 14 
immune resistance to bacterial pathogens, and particularly M.tb. Type II IFN, IFN-γ, 15 
is crucial for protection against M.tb infection, with mutations within the IFN-γ-16 
signalling pathway lead to severe susceptibility to M.tb infection in humans and mice 17 
[35, 36]. Type I IFNs have roles in anti-viral immunity and modulatory functions in 18 
innate and adaptive immunity [37], though their role in M.tb infection is less clear. 19 
IFN-α/β have been observed to have an antagonistic effect on IFN-γ signalling and to 20 
down-regulate ifngr expression leading to more severe disease [38]. Type I IFN 21 
signalling may be a critical link between the host and virulent M.tb pathogen. The 22 
secretion of some mycobacterial products by virulent M.tb strains may induce type I 23 
IFN inducible genes and this may be associated with more severe disease [39]. The 24 
interaction between M.tb and the host type I IFN signalling pathway is crucial in 25 
 16 
determining successful infection, and further elucidation of this pathway may yield 1 
novel therapeutic targets. 2 
 3 
A major challenge to the control of TB is the effective diagnosis of M.tb-infected 4 
individuals. The presence of type I IFN inducible proteins in MPs derived from M.tb 5 
infected cells correlates well with recent transcriptomic studies of patient blood 6 
samples [19-21]. Recent studies have produced transcript sets to distinguish active 7 
TB, from latent TB infection (LTBI) and other respiratory diseases [19, 21]. A 8 
consistent finding was the profound increase in type I inducible gene expression 9 
associated with active TB, including ISG15 and IFITs [19, 21]. Incorporating 10 
detection of a type I IFN inducible signature at both transcript and protein level may 11 
be an effective biomarker for active TB infection and for LTBI patients with potential 12 
risk of reactivation. 13 
 14 
Our analysis of the MP proteome derived from M.tb infected cells provides candidate 15 
biomarkers for TB diagnosis, including type I IFN inducible proteins (ISG15, IFITs) 16 
and phagosome-associated proteins (Fig. 4). All require further evaluation in blood 17 
samples from patients with active TB. Further characterisation of the nucleic acid 18 
content of MPs and the molecular events dictating the MP-induced proinflammatory 19 
response may reveal key insights into the innate immune response to M.tb, as well as 20 
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Figure 1. Protein-protein interaction and functional clustering of proteins displaying 1 
increased abundances in TBinf-MP. Cluster analysis was performed using String 2 
(v9.1) with the additional assistance of KEGG and gene ontology data. Distinct 3 
clusters of proteins associated with immune function, endosomes and lysosomes, 4 
vesicular formation, protein maturation and antigen presentation, histone proteins, 5 
mitochondria, and ribosomal proteins. 6 
 7 
 8 
Figure 2. M. tb infection of THP-1 cells leads to increased gene expression of isg15, 9 
ifit1, ifit2, ifit3, ifitm1/3 and ip10 (A), and increased free-ISG15 protein and ISG15-10 
conjugated proteins (B and C). A representative western blot is shown (B) with the 11 
combined results of densitometry graphed (C). Analyses were performed on 12 
biological duplicates with three technical replicates (n=6). Statistical significance was 13 
determined by one-way ANOVA. *, p < 0.05, **, p < 0.0001. 14 
 15 
 16 
Figure 3. MPs derived from M. tb-infected THP-1 cells induce isg15, ifit1, and ifit2 17 
gene expression (A) and proinflammatory cytokine production (B). PMA 18 
differentiated THP-1 cells were stimulated with TBinf-MP or UI-MPs at a 5:1 19 
MP:cell ratio to determine gene expression of isg15, ifit1, ifit2, ifit3, ifitm1/3 and ip10 20 
and IL-8, IP-10 and MIP-1 cytokine expression (CBA analysis).  Analysis was 21 
performed on biological duplicates with three technical replicates (n=6). Statistical 22 
significance was determined by one-way ANOVA. *, p < 0.01, **, p < 0.001, ***, p 23 
< 0.0001. 24 
 24 
Figure 4. Model of intercellular signaling mediated by MPs following M.tb infection. 1 
1) Infection of the macrophage by M.tb induces expression of type I IFN inducible 2 
genes (i.e. isg15, ifits) and arrest of the phagosome that aids bacterial survival and 3 
results in retention of Rab GTPases (Rab5, Rab14), CD63 and LAMP2; 2) MPs 4 
contain proteins indicative of the infected cell of origin; 3) MPs mediate signaling to 5 
recipient cells (macrophages plus other cell types, e.g. T cells) to enhance the 6 
response to M.tb infection; 4) In recipient macrophages, MPs induce type I interferon 7 
inducible gene expression (i.e. isg15, ifits) and release of proinflammatory cytokines/ 8 
chemokines. 9 
 25 
Table 1: Proteins with increased abundances in MPs derived from M. tb infected 1 
THP-1 cells. Spectral counting analysis was performed on six biological replicates on 2 
the QSTAR Elite. Spectral counts for LTQ-Orbitrap velos correspond to a single run. 3 
Protein 
ID 
QSTAR Elite Analysis 
LTQ-Orbitrap Velos 
Analysis   
TB MP 
Tot. Spec. Cntsa,b 
UI MP 






















       
HLA-A (31,25,38,9,23,32) (11,11,28,12,15,30) 0.012 1.58 157 128 1.23 Y N 
FN1 (1,0,58,33,3,25) (0,0,13,20,0,13) 0.017 2.66 nd nd na Y N 
IFIT1 (7,8,2,1,7,1) (0,0,0,0,0,0) na + 17 4 4.25 N Y 
IFIT2 (2,3,0,0,4,0) (0,0,0,0,0,0) na + 10 0 + N Y 
IFIT3 (6,5,1,3,8,0) (0,0,0,0,0,0) na + 20 0 + N Y 
ISG15 (5,4,0,2,6,0) (0,0,0,0,0,0) na + 11 6 1.83 N Y 
HM13 (1,1,1,2,2,1) (0,0,0,0,0,0) na + 3 3 1.00 N N 
IFITM3 nd nd na na 17 12 1.42 Y N 
PLSCR1 nd nd na na 9 4 2.25 Y Y 
Lysosomal associated 
       
CD63 (10,12,16,7,14,2) (4,4,10,7,9,0) 0.018 1.72 19 11 1.73 Y N 
LAMP2 (8,8,3,4,4,2) (3,3,1,3,3,1) 0.021 2.10 16 11 1.45 Y N 
IL4I1 (2,1,0,0,4,0) (0,0,0,0,0,0) na + 12 0 + N N 
SLC17A5 (2,2,0,1,0,0) (0,0,0,0,0,0) na + 2 0 + N N 
Vesicular formation and trafficking 
       
MYOF (6,3,1,2,8,3) (1,1,1,0,2,4) 0.038 2.46 27 38 -1.41 Y Y 
ANXA6 (5,6,9,15,4,4) (1,1,5,5,2,7) 0.015 2.16 44 30 1.47 Y Y 
RAB5C (11,15,9,13,7,9) (10,6,1,6,8,6) 0.025 1.80 18 19 -1.06 Y N 
RAB7A (15,15,15,15,19,10) (11,9,1,9,15,7) 0.019 1.79 19 14 1.36 Y N 
PDCD6 (11,11,15,8,9,5) (7,5,7,4,10,4) 0.025 1.63 11 12 -1.09 Y N 
CLTC (36,35,40,34,29,93) (15,14,47,39,14,84) 0.049 1.46 52 27 1.93 Y Y 
RAB14 (31,24,26,31,31,16) (27,17,10,14,29,18) 0.028 1.43 16 12 1.33 Y N 
ANXA4 (37,35,39,32,17,11) (21,23,36,18,18,12) 0.022 1.36 31 19 1.63 Y N 
Protein maturation and antigen presentation 
       
PDIA3 (9,7,12,16,12,10) (1,1,4,5,2,4) >0.001 4.08 29 12 2.42 Y N 
CANX (1,2,4,5,1,8) (0,0,1,2,0,2) 0.017 3.97 16 4 4.00 Y N 
PDIA6 (8,6,8,10,5,7) (2,1,3,4,2,3) >0.001 3.09 14 6 2.33 Y N 
HSPA5 (14,15,11,11,11,16) (2,3,6,3,4,11) >0.001 2.90 67 28 2.39 Y N 
P4HB (16,17,6,12,8,9) (4,5,2,7,2,7) >0.001 2.64 33 20 1.65 Y N 
HSP90B1 (12,12,10,10,16,5) (7,7,9,6,8,7) 0.033 1.51 39 22 1.77 Y N 
PPIB (4,3,5,6,5,1) (3,3,1,1,3,1) 0.047 2.01 6 5 1.20 Y N 
ERP29 (5,3,1,4,4,0) (0,0,0,0,0,0) na + 14 3 4.67 Y N 
PDIA4 (0,1,1,1,3,0) (0,0,0,0,0,0) na + 11 14 -1.27 Y N 
Nucleasome/ Nucleus associated 
       
HIST1H2BD (19,20,23,26,6,9) (1,1,7,7,1,7) >0.001 4.59 27 6 4.50 Y N 
HIST1H4A (11,10,24,17,12,9) (1,1,9,4,2,4) >0.001 4.11 33 0 + Y N 
H2AFV (5,7,10,17,1,7) (0,0,4,4,0,3) 0.008 3.35 10 0 + Y N 
H2AFY (0,0,2,3,0,1) (0,0,0,0,0,0) na + 8 0 + Y N 
Other 
       
ANXA5 (52,51,62,51,24,23) (34,35,60,33,29,20) 0.034 1.28 45 36 1.25 Y Y 
VDAC1 (4,4,8,9,2,5) (1,0,6,6,1,2) 0.047 1.84 15 8 1.88 Y N 
a. Tot. spec cnts, total spectral counts 4 
b. Six paired replicate spectral counts are displayed in brackets for the QSTAR analysis  5 
c. Previously identified according to Vesiclepedia (www.microvesicles.org) [15] 6 
d. Put. ISG15 conj., Putative ISG15 conjugate proteins were identified by Zhao et. al (2005) [27] or 7 
Giannakopoulos et al. (2005) [28].  8 
 9 
 26 
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